CuraTeQ Biologics
Biosimilar developer, India. 4 development products across 4 molecules: bevacizumab, filgrastim, pegfilgrastim, trastuzumab.
First approval in the Atlas: Mar 2024, CuraTeQ Biologics Private (INN only), trastuzumab (CDSCO)
FDAproducts approved0
EMAproducts approved3
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved2
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Bevacizumab | CuraTeQ bevacizumab | · | · | · | · | May 2026 | · |
| Filgrastim | Zefylti | · | Feb 2025 | · | · | · | · |
| Pegfilgrastim | Dyrupeg / Cavoley | · | Mar 2025 | · | · | · | · |
| Trastuzumab | Dazublys / CuraTeQ trastuzumab | · | Jun 2025 | · | · | Mar 2024 | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- CDSCOMar 2024CuraTeQ Biologics Private (INN only), trastuzumab
- EMAFeb 2025Zefylti, filgrastim
- EMAMar 2025Dyrupeg, pegfilgrastim
- EMAJun 2025Dazublys, trastuzumab
- CDSCOMay 2026CuraTeQ Biologics Private (INN only), bevacizumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.